When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins.
<h4>Background</h4>We examined sponsorship of published cost-effectiveness analyses of statin use for cardiovascular (CV) prevention, and determined whether the funding source is associated with study conclusions.<h4>Methods and findings</h4>We searched PubMed/MEDLINE (up to...
Saved in:
Main Authors: | Ferrán Catalá-López, Gabriel Sanfélix-Gimeno, Manuel Ridao, Salvador Peiró |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0069462 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PRIMARY PREVENTION OF CARDIOVASCULAR COMPLICATIONS: VALUE OF STATINS
by: S. Y. Martsevich, et al.
Published: (2016-01-01) -
ROSUVASTATIN - THE MOST POTENT STATIN IN CARDIOVASCULAR DISEASE PREVENTION
by: A. E. Semenova, et al.
Published: (2018-06-01) -
RHEUMATOID ARTHRITIS AND CARDIOVASCULAR RISK: PERSPECTIVES OF TREATMENT WITH STATINS
by: D. A. Anichkov, et al.
Published: (2015-12-01) -
Impact of Statin Nonacceptance on Cardiovascular Outcomes in Patients With Diabetes
by: Nisarg Shah, et al.
Published: (2025-06-01) -
Statins and the risk of cataract
by: E. K. Butina, et al.
Published: (2019-12-01)